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Abstract
Background: Levodopa treatment in Parkinson’s disease (PD) increases in serum homocysteine levels due to its metabolism
via catechol O-methyltransferase. Endothelial progenitor cells (EPCs) have the capacity to differentiate into mature
endothelial cells and are markers for endothelial functions and cardiovascular risks. Along with traditional vascular risk
factors, hyperhomocysteinemia is known to decrease the level of EPCs. In the present study, we hypothesized that that
levodopa-induced hyperhomocysteinemia leads to a change in EPC levels.
Methodology/Principal Findings: We prospectively enrolled PD patients who had been prescribed either levodopa/
carbidopa (PD-L group, n=28) or levodopa/carbidopa/COMT inhibitor (PD-LC group, n=25) for more than 1 year. The
number of circulating EPCs was measured by flow cytometry using dual staining of anti-CD34 and anti-KDR antibodies. The
EPCs were divided into tertiles based on their distributions and a logistic regression analysis was used to estimate
independent predictors of the highest tertile of EPCs. The number of endothelial progenitor cells was significantly
decreased in PD-L patients (118699/mL) compared with either PD-LC patients (2696258/mL, p=0.007) or controls
(2066204/mL, p=0.012). The level of homocysteine was significantly increased in PD-L patients (14.965.3 mmol/L)
compared with either PD-LC patients (11.963.0 mmol/L, p=0.028) or controls (11.162.5 mmol/L, p=0.012). The level of
homocysteine was negatively correlated with endothelial progenitor cell levels (r=20.252, p=0.028) and was an
independent predictor of the highest tertile of endothelial progenitor cell levels (OR; 0.749 [95% CI: 0.584–0.961]).
Conclusions/Significance: These data indicate that a higher consumption of EPC for restoration of endothelial damage may
be associated with chronic levodopa treatment in PD patients.
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Introduction
Levodopa treatment is the gold standard therapy in patients
with Parkinson’s disease (PD), with its controlling motor
symptoms, improving quality of life, and prolonging patient’s life-
expectancy. Levodopa therapy, however, causes increase in serum
homocysteine level due to its metabolism via catechol O-
methyltransferase [1]. Hyperhomocysteinemia causes endothelial
dysfunction-mediated vascular impairment and is a risk factor for
vascular disease and cognitive impairment in elderly people [2].
Indeed, recent reports demonstrate that hyperhomocysteinemia in
PD may be associated with an increased prevalence of coronary
artery disease, carotid artery hypertrophy, peripheral neurode-
generation, and increased cerebrovascular resistance [3–6].
Endothelial progenitor cells (EPCs) originate in the bone
marrow, and appear to have the ability to be mobilized and the
capacity to differentiate into mature endothelial cells in response to
vascular trauma and ischemic insults [7]. Additionally, it has been
suggested that circulating EPCs may be a marker for endothelial
function and cardiovascular risk [8]. Along with traditional
vascular risk factors, hyperhomocysteinemia is known to decrease
the level of EPCs [9]. In this study, we compared the EPC levels of
PD patients treated with levodopa and levodopa/COMT inhibitor
to test the hypothesis that hyperhomocysteinemia associated with
chronic levodopa treatment leads to a change in EPC levels.
Methods
Subjects
Fifty-three PD patients and 23 healthy controls were prospec-
tively enrolled from March 2010 to November 2010 at a university
hospital. PD was diagnosed according to the UK Brain Bank
Criteria [10], and patients had been prescribed either levodopa/
carbidopa or levodopa/carbidopa/COMT inhibitor (StalevoH or
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PD patients were divided into a levodopa/carbidopa (PD-L)-
treatment group or a levodopa/carbidopa/COMT inhibitor (PD-
LC)-treatment group. Patients in the PD-LC group were
prescribed either StalevoH or levodopa/carbidopa and ComtanH.
Parkinsonian motor symptoms were assessed using the Unified PD
Rating Scale Part III (UPDRS-III) while patients were in the ‘on’
state, and the total medication dosages were calculated in
levodopa equivalents. All PD patients showed decreased dopamine
transporter uptake in the posterior putamen on 18F-FP-CIT PET
scans. Healthy elderly volunteers who had no active neurological
disorders were recruited by advertisements about the project, or
were healthy relatives of patients with movement disorders or
dementia.
Data on age and gender, medication history (anti-hypertensive
agents, anti-hypoglycemic agents, anti-platelet agents, and statins),
smoking history, lipid profiles, body mass index (BMI, kg/m
2), and
high sensitivity C-reactive protein (CRP) were obtained for all
participants. Subjects with vascular parkinsonism, parkinsonian-
plus syndromes, and PD dementia were excluded. All subjects of
PD patients and controls were also excluded with conditions that
affect EPCs or homocysteine levels, such as cancer, hepatic or
renal insufficiency, symptomatic vascular disease, severe white
matter hyperintensities, or multiple lacunes visible on brain MRIs,
or if they had been prescribed thiazide, anticonvulsants, or
antifolate.
Ethics statements
The study was approved by the Yonsei University Severance
Hospital ethical standards committee on human experimentation.
Written informed consent was also obtained from all participants.
Blood sampling
Blood samples were collected in the morning with fasting state.
Plasma homocysteine concentrations were determined by HPLC
with fluorescence detection. Serum B12 and folate levels were
assessed by immunoassay. After the extraction and purification of
DNA, a PCR was performed for the evaluation of 5, 10-
methylenetetrahydrofolate reductase (MTHFR) genotype [11].
Determination of EPC content
Whole blood (7 ml) was collected in heparin CPT tubes with
pre-established density gradient (Vacutainer Cell Preparation
Tube, BD, Franklin Lakes, NJ) and processed according to the
manufacturer’s instructions. After centrifugation at 8006 g for
20 min at RT, the peripheral blood mononuclear cells (PBMCs)
were isolated, washed with PBS, and counted for recovery and
viability using Trypan Blue. Since EPCs are characterized by the
coexpression of hematopoietic stem cell/progenitor marker
(CD34) and endothelial cell lineage markers (KDR) [12,13], we
determined the content of EPC in PBMC by flow cytometry using
dual staining with fluorescein-conjugated monoclonal antibodies
against CD34/KDR markers (figure 1). Briefly, PBMCs (5 610
5)
were incubated with CD34-FITC/KDR-PE (BD) for 20 min at
4uC in a dark room. Nonspecific binding was determined by
staining an aliquot of cells with fluorescein-conjugated isotype
controls. Following one wash with PBS, cells were fixed with 1%
paraformaldehyde and analyzed by CYTOMICS FC-500 (Beck-
man Coulter, CA). A minimum of 30,000 events was acquired for
each analysis in a list mode file format. The data were analyzed
using CXP analysis software ver. 2.0 (Beckman Coulter). The
absolute counts of EPC were determined by multiplying the
frequency of positive cells determined in cytometric analysis by the
number of lymphocytes and monocytes as determined by complete
blood counts.
Statistics
The Mann-Whitney or Kruskal-Wallis and Fisher’s exact tests
were used to compare categorical and continuous variables among
groups. Pearson’s correlation was conducted to evaluate the
relationship between the levels of EPCs and homocysteine. The
circulating EPCs were divided into tertiles based on their
distributions. A logistic regression analysis in a forward step-wise
manner was used to estimate independent predictors of the highest
tertile of EPCs. For the mode, subjects with EPC levels in the
highest tertile were compared with those in the lower tertile. The
independent variables were age, gender, duration of PD and
levodopa medication, levodopa dosage, UPDRS III, MMSE,
medication use, lipid levels, BMI, genotype, levels of folate and
vitamin B12, and CRP. Statistical analyses were performed using
commercially available software (SPSS, ver. 18.0), and a p-value of
,0.05 was deemed to indicate statistical significance.
Results
The demographic characteristics of the groups are summarized
table 1. No significant differences in age, gender, medication use,
smoking, BMI, K-MMSE, and levels of plasma vitamin B6 and
B12 were observed. HDL levels were higher in controls than in PD
patients. The frequency of the 677C/C and C677C/T genotypes
did not differ significantly between the groups, however, 677T/T
genotype was significantly less prevalent in control subjects (4.3%)
compared with the PD groups (PD-L, 32.1%; PD-LC, 24.0%).
CPR was significantly increased in PD-L patients (2.764.1)
compared with PD-LC patients (1.563.1) or controls (1.162.0).
In patients with PD, no significant differences in medication
Figure 1. Representative flow cytometric analysis of
CD34
+KDR
+ cells. KDR-positive cells are displayed in left and right
upper quadrants (LUQ and RUQ) and CD34-positve cells are displayed in
right upper and lower quadrants (RUQ and RLQ). CD34-and KDR-
positive cells are representative in RUQ.
doi:10.1371/journal.pone.0021536.g001
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3.863.1), levodopa equivalent dosage (633.06230.2 vs.
592.86120.1), and UPDRS III scores (18.968.8 vs. 16.265.9)
were found between PD-L and PD-LC groups, respectively.
However, the daily levodopa dose was higher in the PD-L group
(516.16240.4 vs. 408.06110.5, p=0.025).
The number of EPCs was significantly decreased in PD-L
patients (118699/mL) compared with either PD-LC patients
(2696258/mL, p=0.007) or controls (2066204/mL, p=0.012;
figure 2). The level of homocysteine was significantly increased in
PD-L patients (14.965.3 mmol/L) compared with either PD-LC
patients (11.963.0 mmol/L, p=0.028) or controls (11.16
2.5 mmol/L, p=0.012). Among the EPC tertile subgroups, the
homocysteine level was significantly lower in the highest EPC
tertile compared with the lowest (11.1 6 2.5 vs. 14.0 6 5.5 mmol/
L, p=0.027; figure 3A). The correlation analysis showed that the
level of EPC had a significant negative correlation with the level of
homocysteine (r=20.252, p=0.028; figure 3B). This association
remained significant after adjusting for age (r=20.239, p=0.039),
as age was partially associated with homocysteine levels (r=0.214,
p=0.064). Additionally, the level of homocysteine showed a
positive correlation with levodopa dose (r=0.470, p,0.001) and a
negative correlation with folate (r=20.213, p=0.065) and vitamin
B12 levels (r=20.454, p,0.001).
Logistic regression analysis revealed that homocysteine (OR;
0.749 [95% CI: 0.584–0.961], p=0.023), 677C/C genotype (OR;
9.157 [95% CI: 1.777–47.202], p=0.008), and vitamin B12 (OR;
1.003 [95% CI: 1.001–1.005], p=0.008) were independent
predictors of the highest tertile of EPCs.
Discussion
This is the first study evaluating EPC levels in PD patients
treated chronically with levodopa and levodopa/COMT inhibitor
and their association with homocysteine levels. The major findings
were (1) EPC levels were significantly decreased in the PD-L group
compared with those in the PD-LC group and (2) the level of
homocysteine was negatively correlated with EPC levels and was
an independent predictor of the highest tertile of EPC levels.
These data indicate that a higher consumption of EPC for
Table 1. Demographic characteristics in patients with Parkinson’s disease and controls.
PD-L (n=28) PD-LC (n=25) Control (n=23) p
*
Age (years) 68.565.4 67.266.6 66.864.9 NS
Gender (female) 18 (64.3%) 12 (48.0%) 18 (78.3%) NS
Disease duration (years) 4.464.8 3.863.1 - NS
UPDRS-III 18.968.8 16.265.9 - NS
Duration of levodopa therapy (years) 3.163.8 2.662.9 - NS
Levodopa daily dose (mg/day) 516.16240.4 408.06110.5 - 0.025
COMT inhibitor daily dose (mg/day) - 600.060.0 - -
Levodopa equivalent dose 633.06230.2 592.86120.1 -
BMI (kg/m
2) 24.062.7 23.463.1 24.763.1 NS
Total cholesterol (mg/dL) 189.3646.2 177.0637.8 186.7648.2 NS
Triglyceride (mg/dL) 131.9653.7 119.2645.4 106.1658.1 NS
HDL (mg/dL) 49.2613.0
a 44.868.1
a 67.1633.4 0.007
LDL (mg/dL) 112.9634.0 108.0631.3 111.6628.5 NS
Smoking History 4 (14.3%) 2 (8.3%) 3 (13.0%) NS
Medication use
Anti-hypertensive 12 (42.9%) 11 (44.0%) 12 (52.2%) NS
Anti-hypoglycemic 5 (17.9%) 4 (16.0%) 1 (4.3%) NS
Statins 4 (14.2%) 7 (28.0%) 7 (30.4%) NS
MTHFR genotype
677CC 8 (28.6%) 6 (24.0%) 9 (39.1%) NS
677CT 11 (39.3%) 13 (52.0%) 13 (56.5%) NS
677TT 9 (32.1%) 6 (24.0%) 1 (4.3%) 0.036
Vitamin B12 (pg/ml) 669.16346.1 729.86283.2 774.46299.1 NS
Folate (pg/ml) 9.064.2 10.164.5 10.464.5 NS
CRP 2.764.1 1.563.1 1.162.0 0.035
MMSE 26.862.6 26.663.2 27.062.9 NS
Homocystein (mmol/L) 14.965.3
b 11.963.0 11.162.5 0.012
Values are mean 6 SD. PD-L=Parkinson’s disease with levodopa treatment; PD-LC=Parkinson’s disease with levodopa/COMT inhibitor treatment; BMI=body mass
index; HDL=high-density lipoprotein; LDL=low-density lipoprotein; MMSE=Mini-Mental State Examination.
*The Mann-Whitney and Fisher’s exact tests were used to compare categorical and continuous variables between groups. The Kruskal-Wallis was used compared
continuous variable among group, and the Mann-Whitney test was then performed to compare significant Kruskal-Wallis results:
aFrom controls at p,0.01.
bFrom cases with PD-LC or controls at p,0.05. NS= not significant.
doi:10.1371/journal.pone.0021536.t001
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PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e21536Figure 2. The number of endothelial progenitor cells (EPCs) in patients with PD and controls. Box-and-whisker plot (A) showed that the
number of EPC was significantly decreased in PD patients treated with levodopa compared with PD patients treated with levodopa/COMT inhibitor
(p,0.01) or control subjects (p,0.05). The black horizontal line in each box represents the median, with the boxes representing the interquartile
range and the whiskers represent the maximum. Outliers are recorded individually. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0021536.g002
Figure 3. Association between levels of endothelial progenitor cells (EPCs) and homocysteine. Among the EPC tertile subgroups, the
homocysteine level was significantly lower in the highest EPC tertile compared with the lowest (11.1 6 2.5 vs. 14.0 6 5.5 mmol/L, A). Correlation
analysis of the EPC level showed a significantly negative correlation with the level of homocysteine (B). *p,0.05.
doi:10.1371/journal.pone.0021536.g003
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levodopa treatment in PD patients.
Several factors including smoking, hypertension, hyperhomocys-
teinemia, hypercholesterolemia, diabetes, and cerebrovascular
diseases are known to be associated with low levels of EPCs [9].
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Decreased EPC levels may lead to impaired capacity to repair
endothelium and thus increase the cardiovascular risks associated
with endothelial dysfunctions. In vitro and in vivo studies suggested
that hyperhomocysteinemia had detrimental effects on EPCs
quantitatively and qualitatively through induction of apoptosis or
interference with signaling pathways regulating proliferation,
migration, adhesion and vasculogenetic capacity of EPC [14,15].
Furthermore, clinical studies demonstrated that EPCs had an
inverse relationship with homocysteine levels in patients with
ischemic stroke or controls [15,16]. Nevertheless, those studies
merely provided an association of EPCs and homocysteine levels
that the decrease in EPCs and elevation in homocysteine share a
common cause, not showing a direct causation. The present study
demonstrated that EPC levels were significantly decreased in PD-
LC patients compared with PD-L patients or control subjects, and
the homocysteine level was an independent predictor of the highest
EPC tertile. In this regard, our study may provide a direct causation
between the levels of EPCs and homocysteine since it is well
established that in patients with PD, hyperhomocysteinemia is a
consequence of levodopa therapy, but not of underlying vasculo-
pathy. Interestingly, the levels of EPCs and homocysteine in PD-LC
patients were comparable to those in controls. This may be
secondary to homocysteine-lowering effects by COMT inhibitors
via reducing the O-methylation as previous studies, in which
COMT inhibitor was treated chronically [17,18]. Along with
previous results, our data suggest that an abnormal endothelial
repair process is associated with chronic levodopa treatment-related
hyperhomocysteinemia in patients with PD. Additionally, increased
CRP in PD-L patients compared to controls or PD-LC patients,
which is one of indirect markers of endothelial function, may reflect
partially abnormality of endothelial repair mechanism in these
patients.
Growing evidence suggests that decreased EPC levels are a
significant independent predictor of future cerebrovascular events
or atherosclerotic disease progression in patients with coronary
artery or chronic kidney disease [19,20]. In this regard, it is
speculated that PD patients receiving levodopa chronically may
have an increased cerebrovascular burden. However, this
association has been controversial because the pathophysiology
of cerebrovascular disease in PD is more complex and multifac-
torial, with both risk and preventive factors; lower prevalence of
smoking and decreased glucose, cholesterol, and blood pressure
levels by levodopa may give a protective role, whereas immobility,
supine hypertension, and levodopa-related hyperhomocysteinemia
may increase cerebrovascular risks [21]. Recently, Jickling and
colleagues [22] reported that decreased numbers of EPCs are
associated with age-related severe white matter hyperintensities,
which is one of the comorbid conditions in PD and more prevalent
in PD patients compared to controls [21]. Accordingly, a
longitudinal study with neuroimaging markers is required to
delineate the association of EPC levels and the future cerebrovas-
cular burden in PD patients chronically receiving levodopa.
Some limitations in the present study need to be considered.
First, the sample size with a large variation of EPC levels and the
effects of outliers may limit the validity of the conclusion. When we
performed subanalysis with elimination of outliers of homocysteine
and EPC in each group, the statistical difference among groups
was still maintained although the statistical power to detect
difference in EPC was decreased. Nevertheless, a large-scale study
is warranted to draw a solid conclusion. Second, despite the
absence of significant differences in demographic characteristics
among groups, we could not completely exclude the influence of
confounding factors on the level of EPCs in PD patients, such as
dietary factors or physical activities associated with PD conditions.
Third, together with the general absence of standardized
techniques or markers to identify EPCs [23], the flow cytometry
technique used in this study has limitations in the measurement of
EPC functional properties compared to cell culture methods, in
which the PBMCs are cultured for several days in conditions that
selectively favor the growth of EPCs. Thus, our results should be
interpreted cautiously with knowledge of the limitations of the flow
cytometry technique. Finally, although homocysteine may be the
best marker of methylation status, measurement of S-adenosyl-
methionine and S-adenosylhomocysteine levels would provide
further information about the mechanism of the homocysteine
effect.
In summary, our study demonstrated that the EPC levels were
significantly decreased in PD patients with levodopa treatment
than in those with levodopa/COMT inhibitors treatment, and the
level of homocysteine was an independent predictor of the highest
tertile of EPC levels. A future longitudinal study with a larger
sample size is needed to delineate the association of EPC levels and
cerebrovascular burden in patients with PD chronically receiving
levodopa.
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